Transplantation of fecal microbiota rich in short chain fatty acids and butyric acid treat cerebral ischemic stroke by regulating gut microbiota

Pharmacological Research

Volumn 148, Issue , 2019, Pages

  Chen, Runzhi ^a   Xu, Ying ^a   Wu, Peng ^a   Zhou, Hao ^a   Lasanajak, Yi ^b   Fang, Yingying ^a   Tang, Lan ^a   Ye, Ling ^a   Li, Xing ^a   Cai, Zheng ^a   Zhao, Jie ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Butyric acid; Cerebral ischemic stroke; Fecal microbiota transplantation; Gut microbiota; Short chain fatty acids

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BUTYRIC ACID; LIPID; METRONIDAZOLE; NEOMYCIN; POLYMYXIN B; SHORT CHAIN FATTY ACID; SODIUM CHLORIDE; VANCOMYCIN; VOLATILE FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FATTY ACID LEVEL; FECAL MICROBIOTA TRANSPLANTATION; INTESTINE FLORA; LACTOBACILLUS; LIPID BLOOD LEVEL; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SUPPLEMENTATION; ANIMAL; CEREBROVASCULAR ACCIDENT; FECES; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN ISCHEMIA; BUTYRIC ACID; FATTY ACIDS, VOLATILE; FECAL MICROBIOTA TRANSPLANTATION; FECES; GASTROINTESTINAL MICROBIOME; LACTOBACILLUS; MALE; MICROBIOTA; RATS; RATS, SPRAGUE-DAWLEY; STROKE;

EID: 85071571087     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2019.104403     Document Type: Article

References (72)

1. Rothwell, P.M., Ale, A., Pierre, A., Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 377:9778 (2011), 1681–1692.
2. Sifat, A.E., Vaidya, B., Abbruscato, T.J., Blood-brain barrier protection as a therapeutic strategy for acute ischemic stroke. AAPS J. 19:4 (2017), 957–972.
3. Scherbakov, N., Sandek, A., Ebner, N., Valentova, M., Nave, A.H., Jankowska, E.A., Schefold, J.C., Von, H.S., Anker, S.D., Fietze, I., Sleep-disordered breathing in acute ischemic stroke: a mechanistic link to peripheral endothelial dysfunction. J. Am. Heart Assoc. 6:9 (2017), 1–9.
4. Schaapsmeerders, P., Tuladhar, A.M., Arntz, R.M., Franssen, S., Maaijwee, N.A., Rutten-Jacobs, L.C., Schoonderwaldt, H.C., Dorresteijn, L.D., van Dijk, E.J., Kessels, R.P., Remote Lower White Matter Integrity Increases the Risk of Long-Term Cognitive Impairment After Ischemic Stroke in Young Adults. Stroke 47:10 (2016), 2517–2525.
5. Zhao, L., Wang, R., Song, B., Tan, S., Gao, Y., Fang, H., Lu, J., Xu, Y., Association between atherogenic dyslipidemia and recurrent stroke risk in patients with different subtypes of ischemic stroke. Int. J. Stroke 10:5 (2015), 752–758.
6. Kim, H.A., Yi, H.A., Lee, H., Recent advances in cerebellar ischemic stroke syndromes causing Vertigo and hearing loss. Cerebellum 15:6 (2015), 1–8.
7. Fjetland, L., Kurz, K.D., Roy, S., Kurz, M.W., Evaluation of the recombinant tissue plasminogen activator pretreatment in acute stroke patients with large vessel occlusions treated with the direct bridging approach. Is it worth the effort?. Eur. J. Neurol. 22:2 (2015), 322–327.
8. Hommel, M., Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 334:21 (1996), 1405–1406.
9. C.S.o.N.C.S. Society, Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. Chinese Journal of Neurology 51:9 (2018), 666–673.
10. Koller, R.L., Anderson, D.C., Intravenous thrombolytic therapy for acute ischemic stroke. Weighing the risks and benefits of tissue plasminogen activator 364:22 (2005), 111–127.
11. Sawaguchi, Y., Wang, Z., Ultrasound acceleration of rt-PA thrombolysis depends on acoustic intensity. Biol. Pharm. Bull. 40:1 (2017), 97–103.
12. Tang, H.Y., Li, N., Mao, J.W., Zhu, L., Wang, Y.D., Depression and its risk factors in inpatients with gastrointestinal diseases in department of gastroenterology of general hospital. IEEE International Conference on Control &, Automation, 2014.
13. Hill, J.M., Bhattacharjee, S., Pogue, A.I., Lukiw, W.J., The gastrointestinal tract microbiome and potential link to alzheimer's disease. Front. Neurol. 5:43 (2014), 1–4.
14. Edwards, L.L., Quigley, E.M., Pfeiffer, R.F., Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Semin. Neurol. 17:1 (2011), 10–15.
15. Lechin, F., Van-Der-Dijs, B., Central nervous system plus autonomic nervous system disorders responsible for gastrointestinal and pancreatobiliary diseases. Dig. Dis. Sci. 54:3 (2009), 458–470.
16. Collins, S.M., Bercik, P., The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136:6 (2009), 2003–2014.
17. Salvatore, S., Finazzi, S.A., Tosi, A., Barassi, A., Luini, C., Bettini, B., Zibetti, A., Nespoli, L., Melzi d'Eril, G.V., Multiple sclerosis and celiac disease: is there an increased risk?. Mult. Scler. 10:6 (2004), 711–712.
18. Chen, J., Interaction between microbes and host intestinal health: modulation by dietary nutrients and gut-brain-Endocrine-Immune Axis. Curr. Protein Pept. Sci. 16:7 (2015), 592–603.
19. Premysl, B., The microbiota-gut-brain axis: learning from intestinal bacteria?. Gut 60:3 (2011), 288–289.
20. Israelyan, N., Margolis, K., Reprint of: Serotonin as a Link Between the Gut-Brain-Microbiome Axis in Autism Spectrum Disorders. 2019.
21. Chen, R., Wu, P., Cai, Z., Fang, Y., Zhou, H., Lasanajak, Y., Tang, L., Ye, L., Hou, C., Zhao, J., Puerariae Lobatae Radix with Chuanxiong Rhizoma for treatment of cerebral ischemic stroke by remodeling gut microbiota to regulate the brain–gut barriers. J. Nutr. Biochem. 65 (2019), 101–114.
22. O'Mahony, S.M., Clarke, G., Borre, Y.E., Dinan, T.G., Cryan, J.F., Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav. Brain Res. 277:15 (2014), 32–48.
23. Jameson, K.G., Hsiao, E.Y., Linking the gut microbiota to a brain neurotransmitter. Trends Neurosci. 41:7 (2018), 413–414.
24. Yissachar, N., Yan, Z., Ung, L., Lai, N.Y., Mohan, J.F., Ehrlicher, A., Weitz, D.A., Kasper, D.L., Chiu, I.M., Mathis, D., An intestinal organ culture system uncovers a role for the nervous system in Microbe-Immune Crosstalk. Cell 168:6 (2017), 1135–1148.
25. Longa, E.Z., Weinstein, P.R., Carlson, S., Cummins, R., Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:1 (1989), 84–91.
26. O'Donnell, M.E., Tran, L., Lam, T.I., Liu, X.B., Anderson, S.E., Bumetanide inhibition of the blood-brain barrier Na-K-Cl cotransporter reduces edema formation in the rat middle cerebral artery occlusion model of stroke. J. Cerebral Blood Flow & Metabolism 24:9 (2004), 1046–1056.
27. Adachi, Y., Moore, L.E., Bradford, B.U., Gao, W., Thurman, R.G., Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 108:1 (1995), 218–224.
28. Hu, J., Luo, H., Wang, J., Tang, W., Lu, J., Wu, S., Xiong, Z., Yang, G., Chen, Z., Lan, T., Enteric dysbiosis-linked gut barrier disruption triggers early renal injury induced by chronic high salt feeding in mice. Experimental & Molecular Medicine, 49(8), 2017, e370.
29. Zou, J., Chassaing, B., Singh, V., Pellizzon, M., Ricci, M., Fythe, M.D., Kumar, M.V., Gewirtz, A.T., Fiber-Mediated Nourishment of Gut Microbiota Protects against Diet-Induced Obesity by Restoring IL-22-Mediated Colonic Health. Cell Host & Microbe 23:1 (2017), 41–53.
30. Tan, L., Huangxian, J.U., Jieshou, L.I., Extraction and determination of short-chain fatty acids in biological samples. Chin. J. Chromatography 24:1 (2006), 81–87.
31. Ergul, A., Hafez, S., Fouda, A., Fagan, S.C., Impact of comorbidities on acute injury and recovery in preclinical stroke research: focus on hypertension and diabetes. Translational Stroke Research 7:4 (2016), 248–260.
32. Winek, K., Dirnagl, U., Meisel, A., The gut microbiome as therapeutic target in central nervous system diseases: implications for stroke. Neurotherapeutics J. Am. Society for Experimental NeuroTherapeutics 13:4 (2016), 762–774.
33. Sampson, T., Debelius, J., Thron, T., Janssen, S., Shastri, G., Ilhan, Z.E., Challis, C., Schretter, C., Rocha, S., Gradinaru, V., Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson's disease. Cell 167:6 (2016), 1469–1480.
34. Rogers, G.B., Keating, D.J., Young, R.L., Wong, M.L., Licinio, J., Wesselingh, S., From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry 21:6 (2016), 738–748.
35. Ridler, C., Gut microbiota: gut bacteria affect post-ischaemic inflammation in stroke by modulating intestinal T cells. Nat Rev Gastroenterol Hepatol 13:5 (2016), 250–255.
36. Lin, A., Zheng, W., He, Y., Tang, W., Wei, X., He, R., Huang, W., Su, Y., Huang, Y., Zhou, H., Xie, H., Gut microbiota in patients with Parkinson's disease in southern China. Parkinsonism & related disorders 53 (2018), 82–88.
37. Zuo, T., Wong, S.H., Cheung, C.P., Lam, K., Ng, S.C., Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nature Communications 9:1 (2018), 3663–3675.
38. Kapur, A., Fecal microbiota transplantation for treating recurrent Clostridium difficile infection. Managed Care 22:6 (2013), 18–19.
39. Faith, R., Neil, S., Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therapeutic Advances in Gastroenterology 5:6 (2012), 403–421.
40. Ananthaswamy, A., Faecal transplant eases symptoms of Parkinson's disease. New Scientist 209:2796 (2011), 8–9.
41. Kang, D.W., Adams, J.B., Gregory, A.C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., Mcdonough-Means, S., Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 5:1 (2017), 10–26.
42. Aroniadis, O.C., Brandt, L.J., Fecal microbiota transplantation: past, present and future. Med J Aust 29:1 (2013), 79–84.
43. Russo, R., Cristiano, C., Avagliano, C., De, C.C., La, R.G., Raso, G.M., Canani, R.B., Meli, R., Calignano, A., Gut-brain axis: role of lipids in the regulation of inflammation, pain and CNS diseases. Current Medicinal Chemistry 25:32 (2018), 3930–3952.
44. Maqsood, R., Stone, T.W., The gut-brain Axis, bdnf, NMDA and CNS disorders. Neurochemical Research 41:11 (2016), 2819–2835.
45. Kim, M.H., Kang, S.G., Park, J.H., Yanagisawa, M., Chang, H.K., Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology 145:2 (2013), 396–406.
46. Kotani, A., Miyaguchi, Y., Kohama, M., Ohtsuka, T., Shiratori, T., Kusu, F., Determination of short-chain fatty acids in rat and human feces by high-performance liquid chromatography with electrochemical detection. Analytical Sciences the International Journal of the Japan Society for Analytical Chemistry 25:8 (2009), 1007–1011.
47. Yuan, H., Chen, Y., Zhang, H., Jiang, S., Zhou, Q., Gu, G., Improved bioproduction of short-chain fatty acids (SCFAs) from excess sludge under alkaline conditions. Environmental Science & Technology 40:6 (2006), 2025–2029.
48. Garcia, A., Olmo, B., Lopez-Gonzalvez, A., Cornejo, L., Rupérez, F.J., Barbas, C., Capillary electrophoresis for short chain organic acids in faeces Reference values in a Mediterranean elderly population. Journal of Pharmaceutical & Biomedical Analysis 46:2 (2008), 356–361.
49. Smith, E.A., Macfarlane, G.T., Dissimilatory amino acid metabolism in human colonic Bacteria. Anaerobe 3:5 (1997), 327–337.
50. Sharma, S., Taliyan, R., Singh, S., Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: modulation of histone deacetylase activity. Behavioural Brain Research 291 (2015), 306–314.
51. Liu, H., Zhang, J.J., Li, X., Yang, Y., Xie, X.F., Hu, K., Post-occlusion administration of sodium butyrate attenuates cognitive impairment in a rat model of chronic cerebral hypoperfusion. Pharmacology Biochemistry & Behavior 135 (2015), 53–59.
52. Samira Silva, V., Roger Bitencourt, V., Camila Orlandi, A., Gustavo Colombo, D.P., Tamara Sarate, B., Josiane, B., Gislaine Zilli, R., Joao, Q., Sodium butyrate functions as an antidepressant and improves cognition with enhanced neurotrophic expression in models of maternal deprivation and chronic mild stress. Current Neurovascular Research 11:4 (2014), 359–366.
53. Intlekofer, K.A., Berchtold, N.C., Malvaez, M., Carlos, A.J., Mcquown, S.C., Cunningham, M.J., Wood, M.A., Cotman, C.W., Exercise and sodium butyrate transform a subthreshold learning event into long-term memory via a brain-derived neurotrophic factor-dependent mechanism. Neuropsychopharmacology 38:10 (2013), 2027–2034.
54. Song, M.X., Zhang, Y., Wang, F., Wang, H., Bao, J.F., Sodium butyrate improved cognitive and affective disorder of PD model mice mainly via maintenance of histone acetylation homeostasis. Chinese Pharmacological Bulletin 50:4 (2012), 342–345.
55. Pallavi, R., Jessica, S., Meghan, H., Yin, G., Schahram, A., King, J.A., The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacology 62:7 (2012), 2408–2411.
56. Patnala, R., Arumugam, T.V., Gupta, N., Dheen, S.T., HDAC inhibitor sodium butyrate-mediated epigenetic regulation enhances neuroprotective function of microglia during ischemic stroke. Molecular Neurobiology 54:8 (2016), 1–21.
57. Sharma, S., Taliyan, R., Singh, S., Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: modulation of histone deacetylase activity. Behav Brain Res 291 (2015), 306–314.
58. An-Hsun, C., Si-Ying, C., Tu-Hsueh, Y., Yi-Hsin, W., Hung-Li, W., HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiology of Disease 41:2 (2011), 481–488.
59. Cani, P.D., Human gut microbiome: hopes, threats and promises. Gut 67 (2018), 1716–1725.
60. Cani, P.D., Gut cell metabolism shapes the microbiome. Science, 357(6351), 2017, 548.
61. Tan, J., Mckenzie, C., Potamitis, M., Thorburn, A.N., Mackay, C.R., Macia, L., The role of short-chain fatty acids in health and disease. Advances in Immunology 121:2 (2014), 91–119.
62. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., Backhed, F., From dietary Fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165:6 (2016), 1332–1345.
63. Sumner, C.J., Huynh, T.N., Markowitz, J.A., Perhac, J.S., Hill, B., Coovert, D.D., Schussler, K., Chen, X., Jarecki, J., Burghes, A.H., Taylor, J.P., Fischbeck, K.H., Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Annals of neurology 54:5 (2003), 647–654.
64. Wells, J.M., Brummer, R.J., Derrien, M., Macdonald, T.T., Troost, F., Cani, P.D., Theodorou, V., Dekker, J., Méheust, A., de Vos, W.M., Homeostasis of the gut barrier and potential biomarkers. American Journal of Physiology Gastrointestinal & Liver Physiology 312:3 (2017), G171–G193.
65. D'Souza, W.N., Douangpanya, J., Mu, S., Jaeckel, P., Zhang, M., Maxwell, J.R., Rottman, J.B., Labitzke, K., Willee, A., Beckmann, H., Differing roles for short chain fatty acids and GPR43 agonism in the regulation of intestinal barrier function and immune responses. Plos One, 12(7), 2017, e0180190.
66. Pituch, A., Walkowiak, J., Banaszkiewicz, A., Butyric acid in functional constipation. Gastroenterology Review 8:5 (2013), 295–298.
67. Vlasova, A.N., Chattha, K.S., Kandasamy, S., Liu, Z., Esseili, M., Shao, L., Rajashekara, G., Saif, L.J., Lactobacilli and Bifidobacteria Promote Immune Homeostasis by Modulating Innate Immune Responses to Human Rotavirus in Neonatal Gnotobiotic Pigs. Plos One, 8(10), 2013, e76962.
68. Forssten, S.D., Salazar, N., López, P., Nikkilä, J., Ouwehand, A.C., Patterson, Á., Ruasmadiedo, P., Suarez, A., Gonzalez, S., Gueimonde, M., Influence of a probiotic milk drink, containing Lactobacillus paracasei Lpc-37, on immune function and gut microbiota in elderly subjects. European J. Food Res. Review 1:3 (2011), 159–172.
69. Orrhage, K., Nord, C.E., Bifidobacteria and lactobacilli in human health. Drugs Under Experimental Clinical Res. 26:3 (2000), 95–111.
70. Wanchao, S., Chen, M., Zhiguo, S., Futang, X., Mengmeng, S., Protective effect and mechanism of Lactobacillus on cerebral ischemia reperfusion injury in rats. Braz. J. Med. Biol. Res. 51:7 (2018), 1–7.
71. Zhihua, L., Yanlei, M., Huanlong, Q., Potential prevention and treatment of intestinal barrier dysfunction using active components of Lactobacillus. Annals Surgery 254:5 (2011), 832–833.
72. Miyauchi, E., Morita, H., Tanabe, S., Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo. J. Dairy Sci. 92:6 (2009), 2400–2408.